Trial Profile
A Randomized Phase II Study of Durvalumab (MEDI4736) and Tremelimumab Compared to Doxorubicin in Patients With Advanced or Metastatic Soft Tissue Sarcoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Dec 2023
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary) ; Doxorubicin
- Indications Leiomyosarcoma; Liposarcoma; Malignant fibrous histiocytoma; Soft tissue sarcoma
- Focus Therapeutic Use
- Acronyms MEDISARC
- 24 Oct 2023 Results reporting efficacy and safety data presented at the 48th European Society for Medical Oncology Congress
- 24 Oct 2023 Primary endpoint has not been met. (overall survival (OS)) , according to Results presented at the 48th European Society for Medical Oncology Congress
- 21 Aug 2022 Status changed from active, no longer recruiting to completed.